Mark E. Burkard, MD, PhD close

Mark E. Burkard, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Mark Burkard is an assistant professor of medicine in the Hematology-Oncology section of the UW School of Medicine and Public Health and is a member of the UW Health Breast Center. Dr. Burkard received his medical degree and PhD in chemistry from the University of Rochester. He subsequently trained in internal medicine at New York Hospital-Cornell University and in medical oncology at Memorial Sloan-Kettering Cancer Center. During his oncology fellowship, he studied cell cycle enzymes as novel targets for cancer therapy. He is board certified in Internal Medicine and Medical Oncology. As an oncologist, his clinical practice and research interest is in breast cancer and experimental therapeutics.


Medical Oncology

Breast Cancer


UW Carbone Cancer Center
(608) 266-6400 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
University Hospital
(608) 266-6400 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Medical Oncology
Fellowship Memorial Sloan-Kettering Cancer Center, New York, NY
Medical School University of Rochester School of Medicine, Rochester, NY

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Burkard is interested in targeted therapy directed at protein kinases. His laboratory seeks to link therapies with their targets within cancer cells using genetic tools, and to identify patients whose cancers are most likely to benefit from particular drugs. These studies will be used to inform clinical development of novel agents. Dr. Burkard is part of the breast cancer disease oriented working group.

PubMed Articles
Bernstein MN Ni Z Collins M Burkard ME Kendziorski C Stewart R CHARTS: a web application for characterizing and comparing tumor subpopulations in publicly available single-cell RNA-seq data sets. BMC Bioinformatics . 2021 Feb 23;22(1):83
[PubMed ID: 33622236]
Matson DR Denu RA Zasadil LM Burkard ME Weaver BA Flynn C Stukenberg PT High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability. BMC Cancer . 2021 Feb 23;21(1):186
[PubMed ID: 33622270]
Gilbert A Williams C Azuero A Burkard ME Kenzik K Garrett-Mayer E Meersman S Rocque G Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer. Clin Breast Cancer . 2020 Nov 17;
[PubMed ID: 33309481]
Jin N Lera RF Yan RE Guo F Oxendine K Horner VL Hu Y Wan J Mattison RJ Weaver BA Burkard ME Chromosomal instability upregulates interferon in acute myeloid leukemia. Genes Chromosomes Cancer . 2020 Nov;59(11):627-638
[PubMed ID: 32557940]
Wirth LJ Sherman E Robinson B Solomon B Kang H Lorch J Worden F Brose M Patel J Leboulleux S Godbert Y Barlesi F Morris JC Owonikoko TK Tan DSW Gautschi O Weiss J de la Fouchardière C Burkard ME Laskin J Taylor MH Kroiss M Medioni J Goldman JW Bauer TM Levy B Zhu VW Lakhani N Moreno V Ebata K Nguyen M Heirich D Zhu EY Huang X Yang L Kherani J Rothenberg SM Drilon A Subbiah V Shah MH Cabanillas ME Efficacy of Selpercatinib in <i>RET</i>-Altered Thyroid Cancers. N Engl J Med . 2020 Aug 27;383(9):825-835
[PubMed ID: 32846061]
Parsons BM Meier DR Richmond CS Gurda GT Lofgren KA Burkard ME Deming DA Kenny PA Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. Clin Breast Cancer . 2020 Aug;20(4):e433-e438
[PubMed ID: 32234363]
Singh A Denu RA Wolfe SK Sperger JM Schehr J Witkowsky T Esbona K Chappell RJ Weaver BA Burkard ME Lang JM Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer. Mol Oncol . 2020 Aug;14(8):1898-1909
[PubMed ID: 32255253]
Denu RA Burkard ME Analysis of the "centrosome-ome" identifies MCPH1 deletion as a cause of centrosome amplification in human cancer. Sci Rep . 2020 Jul 17;10(1):11921
[PubMed ID: 32681070]
Rocque GB Gilbert A Williams CP Kenzik KM Nakhmani A Kandhare PG Bhatia S Burkard ME Azuero A Prior Treatment Time Affects Survival Outcomes in Metastatic Breast Cancer. JCO Clin Cancer Inform . 2020 Jun;4:500-513
[PubMed ID: 32479187]
Sharick JT Walsh CM Sprackling CM Pasch CA Pham DL Esbona K Choudhary A Garcia-Valera R Burkard ME McGregor SM Matkowskyj KA Parikh AA Meszoely IM Kelley MC Tsai S Deming DA Skala MC Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Front Oncol . 2020;10:553
[PubMed ID: 32500020]
Johnson JM Hebert AS Drane QH Lera RF Wan J Weaver BA Coon JJ Burkard ME A Genetic Toggle for Chemical Control of Individual Plk1 Substrates. Cell Chem Biol . 2020 Mar 19;27(3):350-362.e8
[PubMed ID: 32017920]
Denu RA Kaur G Sass MM Lakkaraju A Burkard ME Centrosome Amplification in Cancer Disrupts Autophagy and Sensitizes to Autophagy Inhibition. Mol Cancer Res . 2020 Jan;18(1):33-45
[PubMed ID: 31604847]
Lera RF Norman RX Dumont M Dennee A Martin-Koob J Fachinetti D Burkard ME Plk1 protects kinetochore-centromere architecture against microtubule pulling forces. EMBO Rep . 2019 Oct 4;20(10):e48711
[PubMed ID: 31468671]
Pasch CA Favreau PF Yueh AE Babiarz CP Gillette AA Sharick JT Karim MR Nickel KP DeZeeuw AK Sprackling CM Emmerich PB DeStefanis RA Pitera RT Payne SN Korkos DP Clipson L Walsh CM Miller D Carchman EH Burkard ME Lemmon KK Matkowskyj KA Newton MA Ong IM Bassetti MF Kimple RJ Skala MC Deming DA Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. Clin Cancer Res . 2019 Sep 1;25(17):5376-5387
[PubMed ID: 31175091]
Denu RA Sass MM Johnson JM Potts GK Choudhary A Coon JJ Burkard ME Polo-like kinase 4 maintains centriolar satellite integrity by phosphorylation of centrosomal protein 131 (CEP131). J Biol Chem . 2019 Apr 19;294(16):6531-6549
[PubMed ID: 30804208]
Stefely JA Theisen E Hanewall C Scholl L Burkard ME Huttenlocher A Yu JJ A physician-scientist preceptorship in clinical and translational research enhances training and mentorship. BMC Med Educ . 2019 Mar 27;19(1):89
[PubMed ID: 30917818]
Tevaarwerk AJ Hocking WG Buhr KA Gribble M Seaborne LA Wisinski KB Burkard ME Yen T Wiegmann DA Sesto ME A randomized trial of immediate versus delayed survivorship care plan receipt on patient satisfaction and knowledge of diagnosis and treatment. Cancer . 2019 Mar 15;125(6):1000-1007
[PubMed ID: 30690714]
Rocque GB Kandhare PG Williams CP Nakhmani A Azuero A Burkard ME Forero A Bhatia S Kenzik KM Visualization of Sequential Treatments in Metastatic Breast Cancer. JCO Clin Cancer Inform . 2019 Mar;3:1-8
[PubMed ID: 30840488]
Fricke SL Payne SN Favreau PF Kratz JD Pasch CA Foley TM Yueh AE Van De Hey DR Depke MG Korkos DP Sha GC DeStefanis RA Clipson L Burkard ME Lemmon KK Parsons BM Kenny PA Matkowskyj KA Newton MA Skala MC Deming DA MTORC1/2 Inhibition as a Therapeutic Strategy for <i>PIK3CA</i> Mutant Cancers. Mol Cancer Ther . 2019 Feb;18(2):346-355
[PubMed ID: 30425131]
Burkard ME Golden RN Shared Knowledge in Precision Cancer Care. WMJ . 2018 Oct;117(4):178-179
[PubMed ID: 30407771]